DuPont
Executive Summary
Exec-VP and Chief Operating Officer Kurt Landgraf, whose purview formerly included the company's pharmaceutical, agriculture and nutrition businesses, will focus solely on pharmaceuticals following a reorganization announced July 31. DuPont recently announced that it is seeking alliance partners within the pharmaceutical industry (1"The Pink Sheet" March 15, In Brief)
You may also be interested in...
DuPont/Searle joint venture?
DuPont is seeking alliances with pharmaceutical companies for its life science group, the company confirmed, and expects "to be able to conclude one or more of these alliances by the end of this year." The alliance statement comes against the background of recent speculation about a possible merger between DuPont and Searle parent Monsanto ("The Pink Sheet" March 8, p. 16). To highlight its life sciences, DuPont is preparing to create a tracking stock for that segment as early as next year
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials